The angiotensin-endothelin relationship: Does if play a role in cardiovascular and renal pathophysiology?

Journal of Hypertension

Volumn 21, Issue 12, 2003, Pages 2245-2247

  Schiffrin, Ernesto L ^a  

^a CLIN RESEARCH INSTITUTE OF MONTREAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; BOSENTAN; ENDOTHELIN 1; ENDOTHELIN A RECEPTOR ANTAGONIST; ENDOTHELIN B RECEPTOR ANTAGONIST;

DRUG EFFECT; DRUG MECHANISM; EDITORIAL; HUMAN; HYPERTENSION; KIDNEY INJURY; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RENOVASCULAR HYPERTENSION; UPREGULATION;

EID: 1442299088     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004872-200312000-00010     Document Type: Editorial

References (23)

1. Rothermund L. Renal damage is not improved by blockade of endothelin receptors in primary renin-dependent hypertension. J Hypertens 2003; 21:2389-2397.
2. Dohi Y, Hahn AWA, Boulanger CM, Bühler FR, Lüscher TF. Endothelin stimulated by angiotensin II augments contractility of spontaneously hypertensive rat resistance arteries. Hypertension 1992; 19:131-137.
3. Larivière R, Thibault G, Schiffrin EL. Increased endothelin-1 content in blood vessels of deoxycorticosterone acetate-salt hypertensive but not in spontaneously hypertensive rats. Hypertension 1993; 21:294-300.
4. Larivière R, Day R, Schiffrin EL. Increased expression of endothelin-1 gene in blood vessels of deoxycorticosterone acetate-salt hypertensive rats. Hypertension 1993; 21:916-920.
5. Sventek P, Turgeon A, Garcia R, Schiffrin EL. Vascular and cardiac overexpression of endothelin-1 gene in one-kidney one clip Goldblatt hypertensive rats but only in the late phase of two-kidney one clip Goldblatt hypertension. J Hypertens 1996; 14:57-64.
6. Li JS, Knafo L, Turgeon A, Garcia R, Schiffrin EL. Effect of endothelin antagonism on blood pressure and vascular structure in renovascular hypertensive rats. Am J Physiol Heart Circ Physiol 1996; 40:H88-H93.
7. A-selective endothelin receptor antagonism on blood pressure in experimental and genetic hypertension in rats. Br J Pharmacol 1997; 121:935-940.
8. Li JS, Larivière R, Schiffrin EL. Effect of a nonselective endothelin antagonist on vascular remodeling in deoxycorticosterone acetate-salt hypertensive rats. Evidence for a role of endothelin in vascular hypertrophy. Hypertension 1994; 24:183-188.
9. Barton M, D'Uscio LV, Shaw S, Meyer P, Moreau P, Lüscher TF. ETA receptor blockade prevents increased tissue endothelin-1, vascular hypertrophy, and endothelial dysfunction in salt-sensitive hypertension. Hypertension 1998; 31:499-504.
10. Rajagopalan S, Laursen JB, Borthayre A, Kurz S, Keiser J, Haleen S, et al. Role for endothelin-1 in angiotensin II-mediated hypertension. Hypertension 1997; 30:29-34.
11. Moreau P, D'Uscio LV, Shaw S, Takase H, Barton M, Lüscher TF. Angiotensin II increases tissue endothelin and induces vascular hypertrophy - reversal by ETA-receptor antagonist. Circulation 1997; 96: 1593-1597.
12. Hocher B, George I, Rebstock J, Bauch A, Schwarz A, Neumayer HH, Bauer C. Endothelin system-dependent cardiac remodeling in renovascular hypertension. Hypertension 1999; 33:816-822.
13. Deng LY, Schiffrin EL. Endothelin-1 gene expression in blood vessels and kidney of spontaneously hypertensive rats (SHR), L-NAME-treated SHR, and renovascular hypertensive rats. J Cardiovasc Pharmacol 1998; 31 (suppl 1):S380-S383.
14. Muller DN, Mervaala EMA, Schmidt F, Park JK, Dechend R, Genersch E, et al. Effect of bosentan on NF-kappaB, inflammation, and tissue factor in angiotensin II-induced end-organ damage. Hypertension 2000; 36: 282-290.
15. Rossi GP, Sacchetto A, Rizzoni D, Bova S, Porteri E, Mazzocchi G, et al. Blockade of angiotensin II type 1 receptor and not of endothelin receptor prevents hypertension and cardiovascular disease in transgenic (mREN2)27 rats via adrenocortical steroid-independent mechanisms. Arterioscler Thromb Vasc Biol 2000; 20:949-956.
16. Schiffrin EL. Role of endothelin-1 in hypertension and vascular disease. Am J Hypertens 2001; 14:83S-89S.
17. Schiffrin EL, Deng LY, Sventek P, Day R. Enhanced expression of endothelin-1 gene in resistance arteries in severe human essential hypertension. J Hypertens 1997; 15:57-63.
18. Schiffrin EL, Larivière R, Li JS, Sventek P, Touyz RM. Deoxycorticosterone acetate plus salt induces overexpression of vascular endothelin-1 and severe vascular hypertrophy in spontaneously hypertensive rats. Hypertension 1995; 25:769-773.
19. Virdis A, Fritsch Neves M, Amiri F, Viel E, Touyz RM, Schiffrin EL. Spironolactone improves angiotensin-induced vascular changes and oxidative stress. Hypertension 2002; 40:504-510.
20. A receptor antagonist prevents blood pressure elevation and vascular remodeling in aldosterone-infused rats. Hypertension 2001; 37:1444-1449.
21. Muller DN, Mullally A, Dechend R, Park JK, Fiebeler A, Pilz B, et al. Endothelin-converting enzyme inhibition ameliorates angiotensin II-induced cardiac damage. Hypertension 2002; 40:840-846.
22. Benigni A, Zoja C, Corna D, Orisio S, Longaretti L, Bertani T, Remuzzi G. A specific endothelin subtype A receptor antagonist protects against injury in renal disease progression. Kidney Int 1993; 44:440-444.
23. Remuzzi G, Benigni A. Progression of proteinuric diabetic and nondiabetic diseases: a possible role for renal endothelin. Kidney Int 1997; 51:S66-S68.